Susan E. Atkins
CIK: 0002111494
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Atkins Susan E.
Atkins Susan E. (SEC CIK 0002111494) files insider reports with the SEC as Director of BioXcel Therapeutics, Inc. (BTAI) and Director of Jefferson Capital, Inc. / DE (JCAP).
Signal8 holds 3 ownership filings by Atkins Susan E. (2 Form 3, 1 Form 4), filed between Mar 18, 2026 and Aug 14, 2026. Those filings report 1 transaction, the latest on Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Atkins Susan E.'s filings is in NEW HAVEN, CT.
Recent filings by Atkins Susan E.
- Aug 12, 2026: Grant or award of BTAI derivative securities (Form 4, code A).
Other insiders filing for BioXcel Therapeutics, Inc. (BTAI)
- Rodriguez Javier
- Steinhart Richard I, Chief Financial Officer
- Yocca Frank, Chief Scientific Officer
- Mehta Vimal, CEO and President
- Laumas Sandeep, Director
- Patni Rajiv, Director